Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary
According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!
